NZ711603A - Functionalised benzopyran compounds and use thereof - Google Patents

Functionalised benzopyran compounds and use thereof

Info

Publication number
NZ711603A
NZ711603A NZ711603A NZ71160315A NZ711603A NZ 711603 A NZ711603 A NZ 711603A NZ 711603 A NZ711603 A NZ 711603A NZ 71160315 A NZ71160315 A NZ 71160315A NZ 711603 A NZ711603 A NZ 711603A
Authority
NZ
New Zealand
Prior art keywords
functionalised
benzopyran compounds
present
cancer
compounds
Prior art date
Application number
NZ711603A
Other languages
English (en)
Inventor
Andrew Heaton
David Brown
Graham Kelly
Ayesha Alvero
Gil Mor
Original Assignee
Novogen ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen ltd filed Critical Novogen ltd
Publication of NZ711603A publication Critical patent/NZ711603A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ711603A 2014-02-07 2015-02-05 Functionalised benzopyran compounds and use thereof NZ711603A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461937368P 2014-02-07 2014-02-07
US201461987323P 2014-05-01 2014-05-01
PCT/AU2015/050040 WO2015117202A1 (en) 2014-02-07 2015-02-05 Functionalised benzopyran compounds and use thereof

Publications (1)

Publication Number Publication Date
NZ711603A true NZ711603A (en) 2017-05-26

Family

ID=53777071

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ711603A NZ711603A (en) 2014-02-07 2015-02-05 Functionalised benzopyran compounds and use thereof

Country Status (24)

Country Link
US (2) US9701655B2 (enExample)
EP (1) EP2953938B1 (enExample)
JP (1) JP6570042B2 (enExample)
KR (1) KR102395543B1 (enExample)
CN (2) CN105980372B (enExample)
AU (1) AU2015213484B2 (enExample)
BR (1) BR112016018099B8 (enExample)
CA (1) CA2936012C (enExample)
CL (1) CL2016001937A1 (enExample)
DK (1) DK2953938T3 (enExample)
ES (1) ES2643407T3 (enExample)
IL (1) IL241515B (enExample)
LT (1) LT2953938T (enExample)
MX (1) MX368063B (enExample)
MY (1) MY195739A (enExample)
NZ (1) NZ711603A (enExample)
PH (1) PH12016501422B1 (enExample)
PL (1) PL2953938T3 (enExample)
PT (1) PT2953938T (enExample)
RU (1) RU2676766C2 (enExample)
SA (1) SA516371583B1 (enExample)
SG (2) SG11201506988TA (enExample)
SI (1) SI2953938T1 (enExample)
WO (1) WO2015117202A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201506988TA (en) * 2014-02-07 2015-10-29 Novogen ltd Functionalised benzopyran compounds and use thereof
HUE054998T2 (hu) 2015-02-02 2021-10-28 Mei Pharma Inc Kombinációs terápiák emlõrák kezelésében való alkalmazásra
US10265294B2 (en) 2016-03-31 2019-04-23 Yale University Compositions and methods for treating epithelial cancer
EP3439644B1 (en) 2016-04-06 2022-01-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
AU2017247006B2 (en) * 2016-04-06 2022-05-12 Noxopharm Limited Radiotherapy improvements
CN109730996B (zh) * 2017-03-01 2021-08-24 浙江大学 喹啉结构类型雄激素受体拮抗剂及其应用
EP4125870A1 (en) 2020-03-30 2023-02-08 Noxopharm Limited Methods for the treatment of inflammation associated with infection
WO2021252776A1 (en) * 2020-06-11 2021-12-16 Mei Pharma, Inc. Combination therapies
WO2023235929A1 (en) * 2022-06-08 2023-12-14 Noxopharm Limited Functionalised benzopyran compounds and uses thereof
CN118005594B (zh) * 2023-05-24 2024-10-29 内蒙古大学 3-羟基苯并二氢吡喃衍生物的合成及其抗肿瘤活性

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US4447622A (en) 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof
BE891562A (fr) 1981-12-21 1982-04-16 Council Scient Ind Res Isomeres 1 et d de d1-3, 4-trans-3, 4-diarylchromanes 2, 2-disubstitues et leurs derives, leur preparation et leur utilisation
US5280040A (en) 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5451603A (en) 1993-03-11 1995-09-19 Zymogenetics, Inc. 3,4-diarylchromans for treatment of dermatitis
JPH10511960A (ja) 1995-01-13 1998-11-17 ノボ ノルディスク アクティーゼルスカブ 特発性の又は生理学的な女性化乳房の治療又は予防のための医薬製剤の製造のための３，４−ジフェニル・クロマンの使用
HUP9702244A3 (en) 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders
HUP9800521A3 (en) 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or propylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis
CN1168101A (zh) 1995-01-20 1997-12-17 诺沃挪第克公司 3，4-二苯基苯并二氢吡喃制备治疗或预防大脑退化性疾病的药物组合物的用途
TW448046B (en) 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
CA2208852A1 (en) 1995-01-20 1996-07-25 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
IL124882A0 (en) 1996-01-11 1999-01-26 Novo Nordisk As Use of 3, 4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
CN1207038A (zh) 1996-01-11 1999-02-03 诺沃挪第克公司 3,4－二苯基苯并二氢吡喃在生产预防或治疗绝经症状的药物组合物中的应用
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5756539A (en) 1996-07-11 1998-05-26 Novo Nordis A/S 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
US5780502A (en) 1996-07-12 1998-07-14 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
EP0937058A1 (en) 1996-10-28 1999-08-25 Novo Nordisk A/S NOVEL $i(CIS)-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES
US5925771A (en) 1996-10-28 1999-07-20 Novo Nordisk A/S Process for the preparation of (-)-3,4-trans-diarylchromans
US6043269A (en) 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
WO1998018771A1 (en) 1996-10-28 1998-05-07 Novo Nordisk A/S Novel (-)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5919817A (en) 1996-10-28 1999-07-06 Novo Nordisk A/S Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU5550298A (en) 1997-01-29 1998-08-25 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical compositionfor increasing libido in post-menopausal women
WO1998033500A1 (en) 1997-01-29 1998-08-06 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting senescence-associated motor impairment
US6184005B1 (en) 1998-04-28 2001-02-06 Novo Nordisk A/S Enzymatic resolvation for obtaining a (−)-3,4-trans-diarylchroman
RU2232758C2 (ru) * 1998-09-23 2004-07-20 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием
AU6315300A (en) 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
JP2004510815A (ja) 2000-10-13 2004-04-08 アストラゼネカ・アクチエボラーグ エストロゲン受容体−βリガンド
JP4256679B2 (ja) 2001-03-16 2009-04-22 ノボゲン リサーチ ピーティーワイ リミテッド 再狭窄の治療方法
US20050119301A1 (en) 2001-03-16 2005-06-02 Alan Husband Treatment of restenosis
EP1465619A1 (en) 2002-01-14 2004-10-13 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
US20040167165A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-7 receptor
US20060141591A1 (en) 2003-06-04 2006-06-29 Youichi Kyuuko Method for producing optically active chroman-carboxylate
CA2542351A1 (en) * 2003-11-19 2005-06-02 Novogen Research Pty Ltd. Combinational radiotherapy and chemotherapy compositions and methods
JP4976649B2 (ja) * 2004-09-21 2012-07-18 マーシャル エドワーズ，インク． 化合物
NZ553834A (en) 2004-09-21 2010-03-26 Novogen Res Pty Ltd 7-hydroxy-3,4-diphenyl-chroman and chromene derivatives
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
JP4913056B2 (ja) * 2004-09-21 2012-04-11 マーシャル エドワーズ，インコーポレーテッド 置換クロマン誘導体、医薬品、および治療における使用
EP1809618B1 (en) * 2004-09-21 2013-07-17 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
US20090221564A1 (en) 2006-02-21 2009-09-03 Trigen Limited Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease
EP2084141A4 (en) 2006-10-30 2010-07-21 Novogen Res Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
CN101210012B (zh) 2006-12-31 2011-09-14 南华大学 新的含烟酸异黄酮酯衍生物及其制造方法和用途
MX2011002144A (es) 2008-08-29 2011-07-29 Novogen Res Pty Ltd Actividades inmunomoduladoras.
US20100130598A1 (en) 2008-10-22 2010-05-27 Novogen Research Pty Ltd. Methods for inducing programmed cell death
AU2008230055A1 (en) 2008-10-22 2010-05-06 Novogen Research Pty Ltd Methods for Inducing Programmed Cell Death
WO2011115819A2 (en) 2010-03-15 2011-09-22 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same
WO2011156889A1 (en) 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof
ES2773732T3 (es) 2010-11-01 2020-07-14 Mei Pharma Inc Composiciones de isoflavonoides y procedimientos para el tratamiento del cáncer
CN102153535A (zh) 2011-03-04 2011-08-17 中国海洋大学 一种抗肿瘤多药耐药抑制剂苯并吡喃-3-醇酯化衍生物及其制备方法和应用
US20120251630A1 (en) * 2011-03-29 2012-10-04 Marshall Edwards, Inc. Remission therapy of cancer with isoflavonoids
US20150018566A1 (en) * 2011-08-25 2015-01-15 The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy Tubulin binding agents
CN110664816A (zh) 2012-06-07 2020-01-10 佐治亚州立大学研究基金会公司 Seca抑制剂以及其制备和使用方法
CN103408528B (zh) 2013-08-13 2015-04-29 浙江大学 一种色满化合物及其制备方法和应用
CN103450142B (zh) 2013-09-04 2015-03-25 浙江大学 一种色满化合物及其提取方法和应用
CN103585145A (zh) 2013-11-28 2014-02-19 常州科立信医疗器械有限公司 Artoxanthochromane在治疗前列腺癌药物中的应用
CN103638008B (zh) 2013-12-02 2015-09-16 刘艳娇 Artoxanthochromane在治疗皮肤癌药物中的应用
CN103690525A (zh) 2013-12-02 2014-04-02 常州科立信医疗器械有限公司 Artoxanthochromane在治疗舌癌药物中的应用
CN103705503A (zh) 2013-12-04 2014-04-09 常州科立信医疗器械有限公司 Artoxanthochromane在治疗乳腺癌药物中的应用
SG11201506988TA (en) * 2014-02-07 2015-10-29 Novogen ltd Functionalised benzopyran compounds and use thereof

Also Published As

Publication number Publication date
PL2953938T3 (pl) 2017-12-29
JP2017507175A (ja) 2017-03-16
CN105980372B (zh) 2018-05-08
CN108484559A (zh) 2018-09-04
US9701655B2 (en) 2017-07-11
EP2953938A1 (en) 2015-12-16
KR20160110427A (ko) 2016-09-21
RU2676766C2 (ru) 2019-01-11
LT2953938T (lt) 2017-10-10
SG11201604490SA (en) 2016-07-28
CA2936012A1 (en) 2015-08-13
US20160340329A1 (en) 2016-11-24
DK2953938T3 (en) 2017-10-02
AU2015213484A1 (en) 2015-09-17
CL2016001937A1 (es) 2017-01-20
PT2953938T (pt) 2017-10-09
SI2953938T1 (en) 2018-01-31
SG11201506988TA (en) 2015-10-29
MX2016010137A (es) 2017-02-15
MY195739A (en) 2023-02-08
WO2015117202A1 (en) 2015-08-13
MX368063B (es) 2019-09-18
PH12016501422B1 (en) 2022-02-16
ES2643407T3 (es) 2017-11-22
CA2936012C (en) 2023-03-07
BR112016018099A2 (pt) 2017-08-08
IL241515A0 (en) 2015-11-30
EP2953938A4 (en) 2016-08-10
SA516371583B1 (ar) 2019-04-18
RU2016133731A (ru) 2018-03-12
US10370349B2 (en) 2019-08-06
KR102395543B1 (ko) 2022-05-09
AU2015213484B2 (en) 2015-11-05
HK1218914A1 (en) 2017-03-17
EP2953938B1 (en) 2017-08-02
JP6570042B2 (ja) 2019-09-04
BR112016018099B1 (pt) 2022-10-11
US20180141925A1 (en) 2018-05-24
PH12016501422A1 (en) 2016-08-31
CN105980372A (zh) 2016-09-28
BR112016018099B8 (pt) 2023-01-17
IL241515B (en) 2019-06-30
RU2016133731A3 (enExample) 2018-08-08

Similar Documents

Publication Publication Date Title
PH12016501422B1 (en) Functionalised benzopyran compounds and use thereof
IL256874B (en) Immune checkpoint suppressors for use in the treatment of blood-borne cancers
EP3166640A4 (en) Combination therapy compositions and methods for treating cancers
TW201613648A (en) Compounds and compositions for immunotherapy
NZ731467A (en) Anti-tim3 antibodies and methods of use
IL253979B (en) Methods, preparations and kits for cancer treatment
MA39906A (fr) Polythérapies pour le traitement du cancer
EP3222278A4 (en) Use of azelnidipine in preparing medicinal composition for treating cancers
MX375221B (es) Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer.
EP3169363A4 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2016016881A (es) Anticuerpos que se unen a axl.
IL276733A (en) Use of Aribolin in cancer treatment
EP3200815A4 (en) Methods and compositions for treating cancer
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
PH12016501838A1 (en) Compounds and their methods of use
EP3169333A4 (en) Methods and compositions for enhancing cancer therapy
PL3258931T3 (pl) Zastosowanie kabazitakselu w leczeniu nowotworu złośliwego prostaty
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
EP3160591A4 (en) Compositions and methods for treating cancer
GB2546703A (en) Compounds
HK1242965A1 (en) Apilimod for use in the treatment of colorectal cancer
ZA201403006B (en) Composition for use in treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 FEB 2020 BY CPA GLOBAL

Effective date: 20181220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 FEB 2021 BY CPA GLOBAL

Effective date: 20191219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 FEB 2022 BY CPA GLOBAL

Effective date: 20201224

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 FEB 2023 BY CPA GLOBAL

Effective date: 20211223

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 FEB 2024 BY CPA GLOBAL

Effective date: 20221224

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 FEB 2025 BY CPA GLOBAL

Effective date: 20231221

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 FEB 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241219

ASS Change of ownership

Owner name: VIVESTO AB (PUBL), SE

Effective date: 20250804